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The cost-beneﬁt ratio was calculated as the cost per ACR20
response rate by dividing the average annual treatment cost by
the ACR response rate. RESULTS: In a cost-beneﬁt analysis,
RTX was found to have the lowest cost (in $ARS) per ACR20
response rate relative to current biologic therapies: RTX +
MTX = $58,577; INFL + MTX = $79,038; ADAL + MTX =
$83,035 and ETAN + MTX = $84,708. If RTX was introduced
following an inadequate response to 1.5 TNF inhibitors the
cost-beneﬁt ratio was $66,617 and this increased to $80,892
following 2 prior TNF inhibitors. CONCLUSION: These results
conﬁrm that, compared with current biologic agents RTX has the
superior cost-beneﬁt proﬁle. The cost-beneﬁt of RTX is maxi-
mised the earlier RTX is introduced, ie. following an inadequate
response to one prior TNF-inhibitor instead of two. [1] Kremer
JM, Tony HP, Tak PP et al. ACR 2006 (Abstract 0133).
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OBJECTIVES: To evaluate the relationship between switching
patterns among anti-TNFs and health care costs in rheumatoid
arthritis (RA) patients. METHODS: A retrospective study utiliz-
ing the PharMetrics managed-care claims database was con-
ducted. The ﬁrst anti-TNF encounter among RA patients
between January 1, 2001 and January 1, 2004 was identiﬁed.
Patients were required to have a minimum of 12-months of
continuous plan-eligibility prior to and following their index
date. RA-related health care costs were compared between two
mutually exclusive cohorts: patients who switched to another
anti-TNFs versus patients who did not switch. Descriptive and
Chi-square statistical analyses were conducted to determine if
differences existed between the two cohorts. Multivariate analy-
sis was performed to adjust for confounding factors. RESULTS:
In total, 2231 patients were analyzed. Over two-thirds of all
patients were female; the mean age was 50.2 years. The Charlson
Co-morbidity Index (CCI) and disease staging were similar
between the two cohorts. During the 12-month follow-up, 207
patients (9.3%) were switched from one anti-TNF to another.
The average time before switching was 187 days. Compared with
patients who did not switch, patients who switched had higher
total health care costs ($19,256 versus $16,753, P = 0.005), phy-
sician visits ($1350 versus $900, P < 0.0001), inpatient hospital-
izations ($1213 versus $899, P = 0.472), ER visits ($33 versus
$30, P = 866), pharmacy costs ($15,478 versus $13,445,
P = 0.001), except outpatient ($402 versus $509, P = 0.511) and
other costs ($704 versus $919, P = 0.598). After adjusting for
age, gender, CCI, and pre-index period health care costs, patients
who switched had signiﬁcantly higher total and medical costs
than patients who did not switch. CONCLUSION: The rate of
switching and time before switching are important measures of
the effectiveness of RA treatment in real world practice. This
study found that switching between anti-TNF therapies is asso-
ciated with higher health care costs.
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OBJECTIVES: In the past years anti-TNF-a drugs have become
a crucial component of the treatment of Rheumatoid Arthritis
(RA). Recent health-policy decisions prove that in Germany
initial choice of agents will increasingly depend on expected
treatment costs and cost-effectiveness. In order to inform deci-
sion making we assessed the cost-effectiveness of Adalimumab
(ADA), Etanercept (ETA), and Inﬂiximab (INF) based on pub-
lished real-world data from the German Biologics Registry.
METHODS: We designed an excel-based model and calculated
the costs per LUNDEX responder month. The LUNDEX score
developed by Kristensen et al. (2006) is combining the propor-
tion of patients fulﬁlling a response criterion (e.g. ACR 20) with
therapy adherence. Our model compares the costs per LUNDEX-
response over six months for the treatment with ADA, ETA and
INF from a payer-perspective. ACR 20 response rates after
six months (INF = 46%, ADA = 50%, ETA = 58%), therapy
adherence therapy (INF = 77%, ADA = 79%, ETA = 82%) and
real-world dosing data (INF = 4 mg/kg body weight, ADA =
40 mg/bw, ETA = 47.5 mg/week) were derived from published
registry data. Drug, administration and lab costs were calculated
using ofﬁcial databases. RESULTS: During the ﬁrst six months,
treatment with INF, ADA or ETA causes costs of 11,151€,
8,542€ and EUR 9,936€, respectively. The LUNDEX index at six
months is 0.357 for INF, 0.395 for ADA and 0.477 for ETA. The
costs per LUNDEX response are 21,626€ for ADA, 21,626€ for
ETA and 31,210€ for INF. The average cost per LUNDEX-
responder month in Germany is 3,901€ for ADA, 3,450€ for ETA
and 5,162€ for INF during the ﬁrst six months of treatment.
CONCLUSION: Our analysis supports decision making based
on a combined measure of response and therapy adherence.
According to German registry data ETA seems to be the most
cost-effective agent. Long-term data on response and adherence
are needed to further assess real-world cost-effectiveness of
TNF-therapy.
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OBJECTIVES: Detect beneﬁts after a procedure modiﬁcations in
Total Knee Arthroplasty (TKA) via a pharmacoeconomic study.
METHODS: In November 2000–September 2006, 258 total
TKA were performed at our Hospital. Until January 2005,
Interax total knee system was used (Group A, 194 knees). Since
then, prostheses system was substituted to Triathlon and a
peripheral nerves blockade technique was implemented by the
anaesthetic staff in addition to usual epidural blockade (Group B,
64 knees). Patients were admitted the same day of the operation,
and discharged when absence of pain or effectively controlled
with oral medication, no bleeding or swelling of the wound, no
need for transfusion and patient agreement. Costs were measured
from a NHS perspective (direct and indirect sanitary costs) and
effectiveness determined in terms of hospital stay, pain, range of
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